Effect of the Comprehensive Addiction and Recovery Act (CARA) on Buprenorphine Prescribing for Opioid Use Disorder among Medicare Beneficiaries with Back Pain.
Hyunkyu Ko, Julie M Fritz, Thomas F Higgins, Darrel S Brodke, Brook I Martin
{"title":"Effect of the Comprehensive Addiction and Recovery Act (CARA) on Buprenorphine Prescribing for Opioid Use Disorder among Medicare Beneficiaries with Back Pain.","authors":"Hyunkyu Ko, Julie M Fritz, Thomas F Higgins, Darrel S Brodke, Brook I Martin","doi":"10.1097/BRS.0000000000005243","DOIUrl":null,"url":null,"abstract":"<p><strong>Study design: </strong>Observational cohort study.</p><p><strong>Objective: </strong>To examine the effects of the Comprehensive Addition and Recovery Act (CARA) on buprenorphine prescribing and opioid use disorder (OUD) among Medicare beneficiaries with back pain.</p><p><strong>Summary of background data: </strong>Enacted in January 2017, CARA extended buprenorphine prescribing authority to Nurse Practitioners (NP) and Physician Assistants (PA) to treat OUD, defined as a physical or psychological dependence on opioids, but adoption varied by state. Leveraging this policy variation, we examined the effect of CARA on buprenorphine prescribing and OUD employing Medicare beneficiaries over age 65 with back pain from 2016 to 2019, and who were eligible for Part D prescription drug benefits. Only buprenorphine and buprenorphine/naloxone combinations that are FDA-approved for OUD treatment were included as our outcome.</p><p><strong>Methods: </strong>A difference-in-difference regression examined the change in buprenorphine prescribing and OUD before and after CARA between states that did and did not expand prescription authority. Subgroup analysis examined treatment effect heterogeneity by gender and race/ethnicity.</p><p><strong>Results: </strong>States that adopted a full scope-of-practice under CARA had a significant increase in buprenorphine prescribing (6.5%, 95%CI: 1.3%, 12.2%) and a reduction in OUD (7.2%, 95%CI: -9.3%, -4.8%) compared to states that did not expand prescribing authority after the policy implementation. States that expanded prescribing authority following CARA had a disproportionate increase in use of buprenorphine and a reduction in OUD among males and Hispanic patients compared to female and White patients. The magnitude of the policy effects increased over time across all groups.</p><p><strong>Conclusions: </strong>CARA was associated with increased buprenorphine prescribing and a reduction in OUD among older adults with back pain. Expanded authorization of prescription of buprenorphine to treat OUD by NPs/PAs in states that have not adopted full scope-of-practice under CARA might effectively reduce OUD, as well as racial/ethnic disparities in buprenorphine prescribing and OUD.</p><p><strong>Level of evidence: </strong>Level 3.</p>","PeriodicalId":22193,"journal":{"name":"Spine","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Spine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BRS.0000000000005243","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Study design: Observational cohort study.
Objective: To examine the effects of the Comprehensive Addition and Recovery Act (CARA) on buprenorphine prescribing and opioid use disorder (OUD) among Medicare beneficiaries with back pain.
Summary of background data: Enacted in January 2017, CARA extended buprenorphine prescribing authority to Nurse Practitioners (NP) and Physician Assistants (PA) to treat OUD, defined as a physical or psychological dependence on opioids, but adoption varied by state. Leveraging this policy variation, we examined the effect of CARA on buprenorphine prescribing and OUD employing Medicare beneficiaries over age 65 with back pain from 2016 to 2019, and who were eligible for Part D prescription drug benefits. Only buprenorphine and buprenorphine/naloxone combinations that are FDA-approved for OUD treatment were included as our outcome.
Methods: A difference-in-difference regression examined the change in buprenorphine prescribing and OUD before and after CARA between states that did and did not expand prescription authority. Subgroup analysis examined treatment effect heterogeneity by gender and race/ethnicity.
Results: States that adopted a full scope-of-practice under CARA had a significant increase in buprenorphine prescribing (6.5%, 95%CI: 1.3%, 12.2%) and a reduction in OUD (7.2%, 95%CI: -9.3%, -4.8%) compared to states that did not expand prescribing authority after the policy implementation. States that expanded prescribing authority following CARA had a disproportionate increase in use of buprenorphine and a reduction in OUD among males and Hispanic patients compared to female and White patients. The magnitude of the policy effects increased over time across all groups.
Conclusions: CARA was associated with increased buprenorphine prescribing and a reduction in OUD among older adults with back pain. Expanded authorization of prescription of buprenorphine to treat OUD by NPs/PAs in states that have not adopted full scope-of-practice under CARA might effectively reduce OUD, as well as racial/ethnic disparities in buprenorphine prescribing and OUD.
期刊介绍：
Lippincott Williams & Wilkins is a leading international publisher of professional health information for physicians, nurses, specialized clinicians and students. For a complete listing of titles currently published by Lippincott Williams & Wilkins and detailed information about print, online, and other offerings, please visit the LWW Online Store.
Recognized internationally as the leading journal in its field, Spine is an international, peer-reviewed, bi-weekly periodical that considers for publication original articles in the field of Spine. It is the leading subspecialty journal for the treatment of spinal disorders. Only original papers are considered for publication with the understanding that they are contributed solely to Spine. The Journal does not publish articles reporting material that has been reported at length elsewhere.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
